Galenic formulations of organic compounds

1. A solid oral dosage form comprising a therapeutically effective amount of aliskiren, or a pharmaceutically acceptable salt thereof, in an amount of more than 46% by weight based on the total weight of the oral dosage form, wherein the oral dosage form is in the form of a tablet and comprises a) an inner phase which is comprising aliskiren or a pharmaceutically acceptable salt thereof, microcrystalline cellulose, polyvinylpyrrolidone, and crosslinked polyvinylpyrrolidone, and b) an outer phase which is comprising crosslinked polyvinylpyrrolidone, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate and wherein the amount of microcrystalline cellulose in the dosage form ranges from 20 to 32% by weight, the amount of crosslinked polyvinylpyrrolidone in the dosage form ranges from 13.5 to 16% by weight, the amount of polyvinylpyrrolidone in the dosage form ranges from 3 to 4% by weight, the amount of colloidal silicon dioxide in the dosage form ranges from 0.4 to 0.6% by weight, and the amount of magnesium stearate in the dosage form ranges from 0.2 up to 5% by weight.

2. The solid oral dosage form according to claim 1 , wherein the tablet further comprises a film coat wherein said film coat comprises a filmcoating material selected from hydroxypropyl methyl cellulose, polyethylene glycols, polyvinylpyrrolidones, polyvinylpyrrolidone-vinyl acetate copolymer, polyvinyl alcohol, and sugar.

3. The solid oral dosage form according to claim 1 , wherein the tablet is chosen from a tablet in the form of multiparticulates, multiparticulate pellets, multiparticulate minitablets, wax matrix systems, polymer matrix tablets, polymer coated tablets, oral osmotic systems, coated tablets, matrix tablets, press-coated tablets, and multilayer tablets.

4. A solid oral dosage form according to claim 1 , wherein the active ingredient is present in an amount of more than 48% by weight.

5. A solid oral dosage form according to claim 1 , wherein the active ingredient is present in an amount ranging from 46 to 60% by weight.

6. A solid oral dosage form according to claim 1 , wherein the active ingredient consists entirely of aliskiren, or a pharmaceutically acceptable salt thereof, and is present in an amount ranging from about 75 to about 600 mg of the free base per unit dosage form.

7. A solid oral dosage form according to claim 1 , wherein the active ingredient consists entirely of aliskiren, or a pharmaceutically acceptable salt thereof, and is present in an amount ranging from about 75 to about 300 mg of the free base per unit dosage form.

8. A solid oral dosage form according to claim 7 , wherein aliskiren is in the form of a hemi-fumarate thereof, and is present in an amount of about 83 mg per unit dosage form.

9. A solid oral dosage form according to claim 8 , wherein aliskiren is in the form of a hemi-fumarate thereof, and is present in an amount of about 166 mg per unit dosage form.

10. A solid oral dosage form according to claim 6 , wherein aliskiren is in the form of a hemi-fumarate thereof, and is present in an amount of about 332 mg per unit dosage form.

11. A solid oral dosage form according to claim 1 for use in the manufacture of a medicament for the treatment of hypertension.

12. A solid oral dosage form according to claim 1 , wherein the active ingredient is present in an amount of more than 46% up to 56% by weight.

13. A solid oral dosage form according to claim 2 , wherein the filmcoating material is hydroxypropyl methyl cellulose.

14. A solid oral dosage form according to claim 2 or 13 , wherein the film coat further comprises additives selected from pigments, dies, titanium dioxide, iron oxides, talc, and polyethylene glycols 3350, 4000, 6000 and 8000.

15. A solid oral dosage form according to claim 2 , wherein the film coat comprises hydroxypropyl methyl cellulose, iron oxide pigments, titanium dioxide, polyethylene glycol, and talc.

16. A solid oral dosage form according to claim 1 comprising

82.875 mg aliskiren hemifumarate;

53.625 mg microcrystalline cellulose;

6 mg polyvinylpyrrolidone;

24.1 mg crosslinked polyvinylpyrrolidone;

0.9 mg colloidal silicon dioxide; and

2.5 mg magnesium stearate.

17. A solid oral dosage form according to claim 1 comprising

165.75 mg aliskiren hemifumarate;

107.25 mg microcrystalline cellulose;

12 mg polyvinylpyrrolidone;

48.2 mg crosslinked polyvinylpyrrolidone;

1.8 mg colloidal silicon dioxide; and

5 mg magnesium stearate.

18. A solid oral dosage form according to claim 1 comprising

331.5 mg aliskiren hemifumarate;

214.5 mg microcrystalline cellulose;

24 mg polyvinylpyrrolidone;

96.4 mg crosslinked polyvinylpyrrolidone;

3.6 mg colloidal silicon dioxide; and

10 mg magnesium stearate.

19. A method for the treatment of hypertension, congestive heart failure, angina, myocardial infarction, artherosclerosis, diabetic nephropathy, diabetic cardiac myopathy, renal insufficiency, peripheral vascular disease, left ventricular hypertrophy, cognitive dysfunction, stroke, headache and chronic heart failure which method comprises administering a therapeutically effective amount of a solid oral dosage form according to claim 1 to a patient in need thereof.

20. A process for the manufacture of a solid oral dosage form according to claim 1 comprising:

1) mixing the active ingredient and microcrystalline cellulose, polyvinylpyrrolidone, and crosslinked polyvinylpyrrolidone and granulating said components with a granulation liquid;

2) drying a resulting granulate;

3) mixing the dried granulate with crosslinked polyvinylpyrrolidone, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate;

4) compressing a resulting mixture to form a solid oral dosage as a core tablet; and

5) optionally coating a resulting core tablet to give a film-coated tablet.